Michél Laverdière

Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever

Thomas J. Walsh, Peter G. Pappas, Drew J. Winston et al. · New England Journal of Medicine · 2002 · 986 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +17

Frequency and Evolution of Azole Resistance in<i>Aspergillus fumigatus</i>Associated with Treatment Failure1

Susan J. Howard, Daša Cerar, Michael J. Anderson et al. · Emerging infectious diseases · 2009 · 749 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Antifungal Therapy Decreases Sensitivity of theAspergillus Galactomannan Enzyme Immunoassay

Kieren A. Marr, Michél Laverdière, Anja Gugel et al. · Clinical Infectious Diseases · 2005 · 467 citations · Full text

Medicine, Infectious Diseases, Microbiology +14

A Double‐Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients

Raleigh A. Bowden, Pranatharthi Chandrasekar, Mary H. White et al. · Clinical Infectious Diseases · 2002 · 332 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16

Randomized Placebo‐Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy

Coleman Rotstein, Eric J. Bow, Michél Laverdière et al. · Clinical Infectious Diseases · 1999 · 267 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15